# ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

> **NCT05743036** · PHASE1 · TERMINATED · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 44 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** ZN-c3
- **DRUG:** Encorafenib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05743036
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-27
- **Primary completion:** 2024-07-16
- **Final completion:** 2025-07-09
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Study terminated due to change in therapeutic landscape.
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743036, "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05743036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*